First in Human, Phase I Trial of ZL-1201 in Subjects with Advanced Cancer

This is a first-in-human, dose escalation trial of ZL-1201. The major aims of the study are to define the safety profile of this new drug, and to determine a recommended dose and schedule for potential additional trials.

Inclusion Criteria:

• Histologically/cytologically confirmed, locally advanced unresectable or metastatic solid tumors and lymphomas that are refractory or intolerant to standard of care therapy, or for which no standard therapy exists.
• Adequate hematologic status
• Adequate coagulation function
• Adequate hepatic function
• Adequate renal function

Exclusion Criteria:

• Known active brain metastases
• Red blood cells transfusion dependence
• Known cardiopulmonary disease
• Pregnant or breast-feeding females
• Any other serious underlying medical